ACS Nano · 2024 · 27 citations · 18 references
PharmacyImmunologyPharmaceuticsDrug DeliveryImmunotherapyNanoparticle Drug DeliveryCancer NanomedicineNanocarriers For TherapeuticsNanomedicineNanoparticle Delivery SystemsNanoparticle DesignNanoparticle FormulationsCancer NanotherapyDrug Release MechanismsMultifunctional NanoparticlesNanoparticle DeliveryNanoparticle Delivery VectorsOff-target Toxicity ReductionRadiation-induced ImmunosuppressionSelf-assembled Nanomaterials
The development of a radioresponsive delivery platform has led to an innovative combination radioimmunotherapy strategy for treating tumors. However, controlling the release of immunomodulators by local radiotherapy in vivo remains a significant challenge in order to minimize off-target toxicity, reduce radiation-induced immunosuppression, and maximize synergistic radioimmunotherapy efficacy. In this study, we report the development of core-cross-linked diselenide nanoparticles (dSeNPs) as carriers for radioresponsive delivery of the toll-like receptors 7/8 agonist through systemic administration to achieve combined radioimmunotherapy of tumors. The dSeNPs were fabricated from a ring-opening reaction between 2,2′-diselenidebis(ethylamine) and the ethylene oxide group of an amphiphilic block copolymer. The diselenide bonds were naturally protected in the core of the self-assembled nanostructure, making the dSeNPs extremely stable in the physiological environment. However, they exhibited dose- and time-dependent radiosensitivity, meaning that X-ray irradiation could spatiotemporally control the release of R848 from the dSeNPs. In vivo results showed that local radioresponsive R848 release from dSeNPs greatly improved the synergistic efficacy of combined radioimmunotherapy via the programmed cooperative immune system activation process. This process included macrophage polarization, dendritic cell maturation, and cytotoxic T cell activation. Our findings suggest that core-cross-linked dSeNPs are a promising platform for combined radiotherapy due to their spatiotemporal controllability of radioresponsive drug release.
18
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor, Andrew J. Rech, Amit Maity et al. · Nature · 2015 · 2.4K citations
Medicine, Cancer Biology, Oncology +14
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci, Bihui Xu, Yu Qiu et al. · Cell · 2016 · 1.2K citations · Full text
Medicine, Cancer Biology, Oncology +16
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Silvia C. Formenti, Nils-Petter Rudqvist, Encouse B. Golden et al. · Nature Medicine · 2018 · 932 citations · Full text